Advertisement

Ganglioside and Phospholipid Content in Normal and Pathological Human Thyroid

  • Paolo Laccetti
  • Domenico Grieco
  • Francesca D’Antonio
  • Angela Mariano
  • Vincenzo Macchia

Abstract

The first step in the action of TSH is the binding of the hormone to a specific receptor in the thyroid plasma membrane (1). Following this event, there is an activation of adenylate cyclase, resulting in increased intracellular cyclic AMP levels (2,3). Cyclic AMP, in turn, interacts with an intracellular target and mediates many of the effects of TSH on the thyroid gland (4). Kohn et al. (5) have recently suggested that gangliosides play an important role in the interaction of TSH with thyroid plasma membrane receptor. Evidence to support this view comes from the demonstration of specific TSH-ganglioside interactions (6), the presence of gangliosides in biologically active systems and their absence in biologically inactive systems (7), and from the reconstitution of a cyclase stimulatory activity by resynthesis of higher order gangliosides in thyroid membranes where a receptor defect has been correlated with a deficiency in higher order gangliosides (8,9).

Keywords

Papillary Carcinoma Human Thyroid Medullary Carcinoma Toxic Adenoma Total Ganglioside 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Pastan I, Roth J, and Macchia V. Proc Nat Acad Sci 56: 1802, 1966.PubMedCrossRefGoogle Scholar
  2. 2.
    Pastan I and Katzen R. Biochem Biophys Res Commun 29: 792, 1967.PubMedCrossRefGoogle Scholar
  3. 3.
    Macchia V and Pastan I. J Biol Chem 242: 1864, 1967.PubMedGoogle Scholar
  4. 4.
    Macchia V, Tamburrini O, and Pastan I. Endocrinology 86: 787, 1970.PubMedCrossRefGoogle Scholar
  5. 5.
    Aloj SM, Lee G, Consiglio E, et al. J Biol Chem 254: 9030, 1979.PubMedGoogle Scholar
  6. 6.
    Mullin BR, Fishman PM, Lee G, et al. Proc Nat Acad Sci 73: 842, 1976.PubMedCrossRefGoogle Scholar
  7. 7.
    Meldolesi MF, Fishman PM, Aloj SM, et al. Proc Nat Acad Sci 73: 4060, 1976CrossRefGoogle Scholar
  8. 8.
    Meldolesi MF and Laccetti P. In, Proc of the Sixth International Congress of Endocrinology, Melbourne, 1980, p 211.Google Scholar
  9. 9.
    Laccetti P, Grollman EF, Aloj SM, et al. Biochem Biophys Res Commun 110: 772, 1983.PubMedCrossRefGoogle Scholar
  10. 10.
    Lee G, Grollman EF, Aloj SM, et al. Biochem Biophys Res Commun 77: 139, 1977.PubMedCrossRefGoogle Scholar
  11. 11.
    Sawada K, Iwamori M, Hara Y, et al. In, Proc of the Sixth International Symposium on Glicoconjugates, Tokyo, 1981, p 101.Google Scholar
  12. 12.
    Bouchon B, Portokalian J, and Bornet H. Biochem Inter 10: 531, 1985.Google Scholar
  13. 13.
    Macchia V and Wolff J. FEBS Letters 10: 219, 1970.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1986

Authors and Affiliations

  • Paolo Laccetti
    • 1
  • Domenico Grieco
    • 1
  • Francesca D’Antonio
    • 1
  • Angela Mariano
    • 1
  • Vincenzo Macchia
    • 1
  1. 1.Centro di Endocrinologia ed Oncologia Sperimentale del C.N.R. Dipartimento di Biologia e Patologia cellulare e molecolare II Medical SchoolUniversity of NaplesNaplesItaly

Personalised recommendations